Otviciclib
Latest Information Update: 28 Jul 2026
At a glance
- Originator University of Innsbruck; Vichem Chemie
- Developer Vichem Chemie
- Class Antineoplastics
- Mechanism of Action CDC2 protein kinase inhibitors; Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase 5 inhibitors; Cyclin-dependent kinase 9 inhibitors; Cyclin-dependent kinase inhibitors; MCL1 protein inhibitors; Pyroptosis modulators; Wnt protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Multiple myeloma; Solid tumours
Highest Development Phases
- No development reported Multiple myeloma; Solid tumours
Most Recent Events
- 28 Jul 2026 No recent reports of development identified for preclinical development in Multiple-myeloma in Hungary (PO)
- 28 Jul 2026 No recent reports of development identified for preclinical development in Solid-tumours in Hungary (PO)
- 08 Jun 2022 Otviciclib is available for licensing as of 08 Jun 2022. https://vichemchemie.com/